Terminated PHASE1 INTERVENTIONAL NCT00724100

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors

Sponsor: Albany Molecular Research, Inc.

Conditions Cancer

Interventions ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)

Updated 7 times since 2017 Last updated: Aug 26, 2014 Started: Sep 30, 2008 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's decision

Other Cancer trials with similar outcome

Browse all Cancer trials

Listed as NCT00724100, this PHASE1 trial focuses on Cancer and remains terminated or withdrawn. Sponsored by Albany Molecular Research, Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Albany Molecular Research, Inc.
Westat

Data source: Albany Molecular Research, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• The Bronx, United States